MedTrace Logo

Imaging Characteristics of Different ⁶⁸Ga-PSMA Probes in Prostate Cancer

NCT07365397 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-01-26

No results posted yet for this study

Summary

This study aims to evaluate the imaging characteristics of \[⁶⁸Ga\]Ga-GS24-B2-250-T Injection (abbreviated as ⁶⁸Ga-GS24-B2-250-T), \[⁶⁸Ga\]Ga-GS24-B2-268-T Injection (abbreviated as ⁶⁸Ga-GS24-B2-268-T), \[⁶⁸Ga\]Ga-GS24-B2-237-T Injection (abbreviated as ⁶⁸Ga-GS24-B2-237-T), and \[⁶⁸Ga\]Ga-PSMA-11 Injection (abbreviated as ⁶⁸Ga-PSMA-11) as PET/CT imaging agents in patients with prostate cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

68Ga-GS24-B2-268-T

detect prostate cancer lesions via 68Ga-GS24-B2-268-T PET/CT imaging

DIAGNOSTIC_TEST

68Ga-GS24-B2-250-T

detect prostate cancer lesions via 68Ga-GS24-B2-250-T PET/CT imaging

DIAGNOSTIC_TEST

68Ga-GS24-B2-237-T

detect prostate cancer lesions via 68Ga-GS24-B2-237-T PET/CT imaging

DIAGNOSTIC_TEST

68Ga-PSMA-11

detect prostate cancer lesions via 68Ga-PSMA-11 PET/CT imaging

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-19
Primary Completion
2026-06-14
Completion
2026-07-26

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07365397 on ClinicalTrials.gov